A 32-year-old woman with severe asthma on long-term oral prednisolone develops iatrogenic Cushing's syndrome. Attempts to taper prednisolone cause worsening asthma. The physician plans to switch to inhaled fluticasone propionate. What pharmacokinetic property specifically minimizes systemic side effects of inhaled fluticasone compared to oral prednisolone?

• A Inhaled fluticasone is absorbed only into bronchial lymphatics and never reaches systemic circulation
• B Fluticasone propionate has high lipophilicity enabling lung retention, but the portion swallowed and any systemically absorbed drug undergoes extensive first-pass metabolism in the liver to inactive metabolites, minimizing systemic bioavailability to less than 1% ✓
• C Fluticasone has extremely high affinity for glucocorticoid receptors in airway epithelium, allowing very low doses to be used
• D Fluticasone is a prodrug activated specifically by esterases in bronchial mucosa and remains inactive if absorbed systemically

Explanation

The key pharmacokinetic property of inhaled corticosteroids (ICS) like fluticasone is their extensive hepatic first-pass metabolism. After inhalation, approximately 10-20% of the dose reaches the lower respiratory tract for therapeutic effect; the remaining 80-90% is deposited in the oropharynx, swallowed, and absorbed. However, fluticasone propionate undergoes >99% first-pass hepatic metabolism (CYP3A4) to the inactive 17beta-carboxylic acid, resulting in oral bioavailability <1%. Even the lung-absorbed fraction enters the portal circulation and is largely inactivated hepatically. Combined with targeted deposition in airways, this nearly eliminates systemic corticosteroid effects. Ciclesonide is another ICS that is a prodrug activated by lung esterases, further minimizing oropharyngeal side effects.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.